118 related articles for article (PubMed ID: 15197908)
1. [How to use anticoagulants in hemodialysis therapy].
Uriu K; Kaizu K
Nihon Rinsho; 2004 May; 62 Suppl 5():163-7. PubMed ID: 15197908
[No Abstract] [Full Text] [Related]
2. [Anticoagulant].
Mitome J; Yamamoto H
Nihon Rinsho; 2004 May; 62 Suppl 5():368-73. PubMed ID: 15197947
[No Abstract] [Full Text] [Related]
3. [Heparin-induced thrombocytopenia in patients on hemodialysis].
Matsuo T
Nihon Rinsho; 2004 Jun; 62 Suppl 6():312-8. PubMed ID: 15250315
[No Abstract] [Full Text] [Related]
4. [Anticoagulation for plasmapheresis].
Amemiya H; Sekihara H; Kobayashi T; Koiwa F; Niikura K
Nihon Rinsho; 2004 May; 62 Suppl 5():323-7. PubMed ID: 15197938
[No Abstract] [Full Text] [Related]
5. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Murphy GS; Marymont JH
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
[No Abstract] [Full Text] [Related]
6. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
Steinfeldt T; Rolfes C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr; 43(4):304-10; quiz 312. PubMed ID: 18409125
[TBL] [Abstract][Full Text] [Related]
7. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
[TBL] [Abstract][Full Text] [Related]
8. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
Kaizu K; Uriu K; Ikeda M
Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
[No Abstract] [Full Text] [Related]
9. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
10. 'Heparin rebound' means the opposite in cardiac surgery (bleeding) and in cardiology (thrombosis).
Koracevic G
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):198-9. PubMed ID: 20118712
[No Abstract] [Full Text] [Related]
11. Unfractionated versus low-molecular-weight heparin for deep venous thrombosis.
Strandness DE
N Engl J Med; 1996 Aug; 335(9):670-1; author reply 671-2. PubMed ID: 8692246
[No Abstract] [Full Text] [Related]
12. Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices. Invited commentary.
Butterworth J
Ann Thorac Surg; 2008 May; 85(5):1655. PubMed ID: 18442559
[No Abstract] [Full Text] [Related]
13. Unfractionated versus low-molecular-weight heparin for deep venous thrombosis.
Penner J
N Engl J Med; 1996 Aug; 335(9):671; author reply 671-2. PubMed ID: 8692247
[No Abstract] [Full Text] [Related]
14. Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin.
Paciaroni M; Ageno W; Agnelli G
Thromb Haemost; 2008 May; 99(5):978-80. PubMed ID: 18449438
[No Abstract] [Full Text] [Related]
15. Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis.
Hara T; Jojima K; Takeuchi K; Takai K; Naito K
Thromb Haemost; 2004 Jul; 92(1):208-10. PubMed ID: 15213863
[No Abstract] [Full Text] [Related]
16. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
[No Abstract] [Full Text] [Related]
17. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W
Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247
[TBL] [Abstract][Full Text] [Related]
18. Guidelines on anticoagulants and the use of LR anesthesia.
Vandermeulen E
Acta Anaesthesiol Belg; 2001; 52(4):425-9. PubMed ID: 11799577
[No Abstract] [Full Text] [Related]
19. Delayed-type hypersensitivity to heparin with tolerance of its intravenous administration.
Irion R; Gall H; Peter RU
Contact Dermatitis; 2000 Oct; 43(4):249-50. PubMed ID: 11011948
[No Abstract] [Full Text] [Related]
20. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
Hirsh J; Warkentin TE; Raschke R; Granger C; Ohman EM; Dalen JE
Chest; 1998 Nov; 114(5 Suppl):489S-510S. PubMed ID: 9822059
[No Abstract] [Full Text] [Related]
[Next] [New Search]
